Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study. (12th May 2020)

• Record Type: Journal Article
• Authors: Sperling, Michael R.; Klein, Pavel; Aboumatar, Sami; Gelfand, Michael; Halford, Jonathan J.; Krauss, Gregory L.; Rosenfeld, William E.; Vossler, David G.; Wechsler, Robert; Borchert, Leona; Kamin, Marc
• Is Part Of: Epilepsia. Volume 61:issue 6(2020)
• Page Start: 1099
• Page End: 1108
• Publication Date: 2020-05-12
• Subjects: antiepileptic drugs -- cenobamate -- DRESS -- refractory epilepsy -- safety/tolerability; Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.16525
• Languages: English
• ISSNs: 0013-9580

Abstract

Abstract: Objective: During the development of cenobamate, an antiseizure medication (ASM) for focal seizures, three cases of drug reaction with eosinophilia and systemic symptoms (DRESS) occurred. To mitigate the rate of DRESS, a start‐low, go‐slow approach was studied in an ongoing, open‐label, multicenter study. Also examined were long‐term safety of cenobamate and a method for managing the pharmacokinetic interaction between cenobamate, a 2C19 inhibitor, and concomitant phenytoin or phenobarbital. Methods: Patients 18‐70 years old with uncontrolled focal seizures taking stable doses of one to three ASMs were enrolled. Cenobamate 12.5 mg/d was initiated and increased at 2‐week intervals to 25, 50, 100, 150, and 200 mg/d. Additional biweekly 50 mg/d increases to 400 mg/d were allowed. During titration, patients taking phenytoin or phenobarbital could not have their cenobamate titration rate or other concomitant ASMs adjusted; phenytoin/phenobarbital doses could be decreased by 25%‐33%. Results: At data cutoff (median treatment duration = 9 months), 1347 patients were enrolled, of whom 269 (20.0%) discontinued, most commonly due to adverse events (n = 137) and consent withdrawn for reason other than adverse event (n = 74); 1339 patients received ≥1 treatment dose (median modal dose = 200 mg). The most common treatment‐emergent adverse events (TEAEs) were somnolence (28.1%), dizziness (23.6%), and fatigue (16.6%). Serious TEAEs occurred in 108 patients (8.1%), most commonly seizure (n = 14), epilepsy (n = 5), and pneumonia, fall, and dizziness (n = 4 each). No cases of DRESS were identified. In the phenytoin/phenobarbital groups, 43.4% (36/114) and 29.7% (11/51) of patients, respectively, had their doses decreased. At the end of titration, mean plasma phenytoin/phenobarbital levels were generally comparable to baseline. Significance: No cases of DRESS were identified in 1339 patients exposed to cenobamate using a start‐low (12.5 mg/d), go‐slow titration approach. Cenobamate was generally well tolerated in the long term, with no new safety issues found. Phenytoin/phenobarbital dose reductions (25%‐33%), when needed during cenobamate titration, maintained stable plasma levels.